Business Wire

CA-JUNIPER-NETWORKS

18.7.2024 09:31:26 CEST | Business Wire | Press release

Share
Telxius Upgrades Its Global Network to 400G With a Converged Optical Routing Architecture by Juniper Networks

Telxius, a leading global connectivity provider, is scaling its core and edge network infrastructure to 400G with a Converged Optical Routing Architecture (CORA) provided by Juniper Networks (NYSE:JNPR), a leader in secure AI-Native Networks. This will enable a simplified network capacity expansion and efficient delivery of enhanced connectivity to metro networks and data center interconnects (DCI). It provides connectivity across distances of around 100 km to points of presence (PoPs) across Telxius’ global footprint in Spain, the Americas, and wider Europe.

Telxius connects millions of customers globally, providing a wide range of capacity, colocation and security services, as well as direct internet connectivity through its Tier-1 IP network. Its extensive ecosystem combines fiber optic submarine cables and terrestrial backhauls together spanning 100,000+ km, almost 100 PoPs in 17 countries, plus 27 data centers. Telxius seamlessly connects customers with ultra-high capacity, low latency and resilient networking.

Telxius will migrate some of its key architecture to Juniper’s CORA and PTX Series Packet Transport Routers to deliver a network that offers robust power and space savings superior performance and automated operations. This will free up a substantial amount of reserved bandwidth and allow for flexible extension to 400G capacity. The project will create enhanced connectivity for Telxius’ customers and create a more sustainable architecture by optimizing network scalability and bandwidth efficiency.

The solution leverages leading edge technology with the use of an IP over Dense Wavelength Division Multiplexing (IPoDWDM) solution. This maximizes routing platform capacity, scales up link bandwidth, and can reach more network locations and customers whilst removing the need to manage and maintain external DWDM equipment.

Using Juniper’s CORA, Telxius will simplify the network architecture by consolidating previously siloed IP and optical network layers into a unified system leveraging IPoDWDM. Once the project is complete, Telxius expects to increase network reliability for its customers, simplify network operations and substantially reduce power consumption.

“This project is a fantastic step forward to bring added scalability and capacity to the Telxius network through 400G coherent pluggable optics, meeting our customers’ needs in today’s ever-growing digital economy. Telxius is at the forefront of innovation, ensuring reduced power consumption and a simplified network architecture to provide a better experience for our customers. We anticipate a number of vendor-agnostic solutions that could support this architecture, and we are excited to collaborate with Juniper to build a solid foundation for further network expansion, said Carlos Dasi, CTO, Telxius.

“400G optics are a highly reliable solution to further enhance Telxius’ infrastructure to enable the best experience for customers. Telxius is leading the way for network innovation with the deployment of Juniper’s PTX and CORA, and Juniper is proud to enable this network transformation. Juniper’s optics solutions provide a simplified integration with Juniper infrastructure that allows the customer to scale up and scale out their network in line with their business goals. Built to last, this network transformation will extend Telxius’ network longevity to future-proof the business,” said Julius Francis, Senior Director of Product Marketing, Juniper Networks.

About Telxius

As the world’s needs for uninterrupted global interconnectivity continue to rise, we are preparing the road ahead. Telxius is a leading global connectivity provider that combines subsea and terrestrial networks with data centers worldwide. Its extensive ecosystem includes eight next-generation fiber optic submarine cables and terrestrial backhauls together spanning 100,000+ km, almost 100 PoPs in 17 countries, plus 25 landing stations. Telxius provides a wide range of capacity, colocation and security services, as well as direct internet connectivity through its Tier-1 IP network. With ultra-high capacity, low latency and resilient networking, Telxius seamlessly connects customers across the Americas, Europe and beyond. For more information about Telxius visit www.telxius.com.

About Juniper Networks

Juniper Networks believes that connectivity is not the same as experiencing a great connection. Juniper's AI-Native Networking Platform is built from the ground up to leverage AI to deliver exceptional, highly secure and sustainable user experiences from the edge to the data center and cloud. Additional information can be found at Juniper Networks (www.juniper.net) or connect with Juniper on X (Twitter), LinkedIn, and Facebook.

Juniper Networks, the Juniper Networks logo, Juniper, Junos, and other trademarks listed here are registered trademarks of Juniper Networks, Inc. and/or its affiliates in the United States and other countries. Other names may be trademarks of their respective owners.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240718748438/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye